

## Envafolimab

Cat. No.:	HY-P99115
CAS No.:	2102192-68-5
Target:	PD-1/PD-L1
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Envafolimab (ASC 22; KN 035) is a recombinant protein of a humanized single-domain anti- PD-L1 antibody. Envafolimab is created by a fusion of the of anti-PD-L1 domain with Fc fragment of human IgG1 antibody. Envafolimab blocks interaction between PD-L1 and PD-1 with an IC <sub>50</sub> value of 5.25 nM. Envafolimab has the potential for the research of solid tumors <sup>[1][2][3]</sup> .
<b>In Vitro</b>	Envafolimab (0-2.51 nM) induces T-cell cytokine (IFN- $\gamma$ ) production in a dose- and time-dependent manner <sup>[3]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>In Vivo</b>	Envafolimab (0.18-0.92 mg/kg; i.p.; four times over 2 weeks) shows antitumor activity with a half-life of ~72 h in NOD-SCID mice (A375 cells) <sup>[3]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Papadopoulos KP, et al. First-in-Human Phase I Study of Envafolimab, a Novel Subcutaneous Single-Domain Anti-PD-L1 Antibody, in Patients with Advanced Solid Tumors. *Oncologist*. 2021 Sep;26(9):e1514-e1525.
- [2]. Akinleye A, et al. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. *J Hematol Oncol*. 2019 Sep 5;12(1):92.
- [3]. Zhang F, Wei H, Wang X, Bai Y, Wang P, Wu J, Jiang X, Wang Y, Cai H, Xu T, Zhou A. Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade. *Cell Discov*. 2017 Mar 7;3:17004.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA